Hospital
Greenfield Area Medical Center
Greenfield Area Medical Center was paid $5.33M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoGREENFIELD AREA MEDICAL CENTER
GREENFIELD, OH 45123
GREENFIELD, OH 45123
33aNPI1215960901assigned 07/08/2006
33bProvider typeCritical Access Hospital
28Total paid$5.33M
24GClaims133,812
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Ohio
Rank by total paid#14 of 26
Median peer was paid$5.33M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,496 | $333K | |
| 2019 | 8,109 | $317K | |
| 2020 | 6,544 | $335K | |
| 2021 | 9,297 | $435K | |
| 2022 | 13,353 | $537K | |
| 2023 | 51,722 | $1.52M | |
| 2024incomplete | 37,291 | $1.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 14,311 | 13,357 | $1.79M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.9% | 3,832 | 3,435 | $474K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.6% | 3,088 | 2,553 | $404K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 2,653 | 1,827 | $327K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.0% | 3,808 | 989 | $267K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.4% | 1,788 | 1,566 | $235K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.5% | 1,812 | 648 | $187K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 661 | 509 | $182K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.3% | 1,912 | 1,384 | $176K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.9% | 1,628 | 551 | $157K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 547 | 415 | $144K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 484 | 381 | $116K |
146 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 803 | $115K |
| 80053 | Comprehensive metabolic panel | 1.3% | 6,477 | $67K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 545 | $52K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 143 | $49K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,739 | $48K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 277 | $43K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,191 | $34K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,298 | $32K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 104 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,127 | $27K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,133 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 833 | $25K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 637 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,409 | $21K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 185 | $17K |
| 73630 | <1% | 447 | $17K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 46 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 935 | $14K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 147 | $14K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 75 | $13K |
| G0378 | Hospital observation service, per hour | <1% | 446 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 607 | $11K |
| 80061 | Lipid panel | <1% | 714 | $11K |
| 73610 | <1% | 296 | $8K | |
| 71250 | <1% | 85 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 381 | $8K |
| 97161 | <1% | 200 | $7K | |
| 72100 | <1% | 134 | $6K | |
| 73130 | <1% | 171 | $6K | |
| 73030 | <1% | 189 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,200 | $4K |
| 73110 | <1% | 109 | $4K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,797 | $4K |
| 83735 | <1% | 1,763 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 28 | $4K |
| 94060 | <1% | 19 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $4K |
| 85610 | <1% | 2,493 | $4K | |
| 82607 | <1% | 171 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,683 | $3K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 14 | $3K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 29 | $3K |
| 87088 | <1% | 1,332 | $3K | |
| 84484 | <1% | 2,389 | $3K | |
| J3490 | Unclassified drugs | <1% | 521 | $3K |
| 71271 | <1% | 12 | $2K | |
| 82248 | <1% | 1,034 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 17 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 27 | $2K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 14 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,126 | $2K |
| 83540 | <1% | 129 | $2K | |
| 82570 | <1% | 208 | $2K | |
| 84466 | <1% | 95 | $2K | |
| 81001 | <1% | 2,965 | $2K | |
| 83880 | <1% | 864 | $1K | |
| 80076 | <1% | 262 | $1K | |
| 84703 | <1% | 956 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $1K |
| 90677 | <1% | 145 | $1K | |
| 90648 | <1% | 147 | $1K | |
| 86803 | <1% | 33 | $1K | |
| 73562 | <1% | 42 | $1K | |
| 82565 | <1% | 93 | $1K | |
| 85027 | <1% | 224 | $1K | |
| 83605 | <1% | 1,670 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,766 | $1K |
| 86140 | <1% | 89 | $1K | |
| 97162 | <1% | 47 | $1K | |
| 82947 | <1% | 923 | $1K | |
| 83655 | <1% | 74 | $782.44 | |
| 11721 | <1% | 48 | $771.91 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 725 | $657.15 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 90 | $640.27 |
| 82728 | <1% | 27 | $623.16 | |
| 90633 | <1% | 64 | $616.00 | |
| 85379 | <1% | 755 | $601.42 | |
| 83690 | <1% | 1,137 | $582.87 | |
| 85730 | <1% | 1,384 | $580.66 | |
| 96376 | <1% | 219 | $552.02 | |
| 90723 | <1% | 117 | $543.59 | |
| 80069 | <1% | 33 | $531.79 | |
| 90680 | <1% | 112 | $517.49 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 26 | $512.35 |
| 82077 | <1% | 302 | $496.20 | |
| 86780 | <1% | 14 | $492.93 | |
| 73502 | <1% | 17 | $490.08 | |
| 82948 | <1% | 588 | $466.79 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 858 | $451.68 |
| 83721 | <1% | 16 | $416.24 | |
| 82803 | <1% | 842 | $415.83 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 17 | $415.56 |
| 82043 | <1% | 54 | $411.56 | |
| 81003 | <1% | 658 | $405.02 | |
| 87186 | <1% | 462 | $382.57 | |
| 84439 | <1% | 13 | $368.99 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 374 | $309.76 |
| 90661 | <1% | 39 | $297.98 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 279 | $249.73 |
| 82550 | <1% | 73 | $245.43 | |
| 90715 | <1% | 25 | $241.50 | |
| 87081 | <1% | 307 | $238.36 | |
| 87040 | <1% | 635 | $234.26 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,201 | $232.82 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 14 | $219.46 |
| 87420 | <1% | 197 | $216.72 | |
| 85652 | <1% | 45 | $203.02 | |
| 84702 | <1% | 14 | $196.26 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 204 | $192.54 |
| 90381 | <1% | 21 | $177.50 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,239 | $122.70 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 59 | $121.71 |
| 73080 | <1% | 13 | $114.40 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 137 | $99.16 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 27 | $70.20 |
| 82150 | <1% | 56 | $61.16 | |
| 90461 | <1% | 211 | $55.36 | |
| 87430 | <1% | 95 | $54.51 | |
| 87400 | <1% | 166 | $53.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,069 | $46.25 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 48 | $36.12 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 28 | $35.86 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 89 | $20.44 |
| 81025 | <1% | 78 | $19.35 | |
| 85018 | <1% | 52 | $16.98 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,315 | $11.55 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 40 | $5.74 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 363 | $4.56 |
| 36416 | <1% | 22 | $4.26 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 126 | $2.65 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 77 | $1.93 |
| 87205 | <1% | 15 | $1.17 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 16 | $1.11 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 255 | $1.09 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 38 | $0.42 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 178 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 702 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 122 | $0.00 |
| 94760 | 0% | 61 | $0.00 | |
| 87280 | 0% | 47 | $0.00 | |
| 94761 | 0% | 92 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| 87147 | 0% | 35 | $0.00 | |
| 87077 | 0% | 28 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 26 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCMANUS, JAMES (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Adena Hospice, LLC | Chillicothe, OH | $1.06M |
| Adena Home Health, LLC | Chillicothe, OH | $867K |
| Multicare Health System | Everett, WA | $60K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.